At Pfizer Singapore, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world’s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care in Singapore.
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company develops innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD has 65,000 employees and a presence in virtually every country around the world to address some of the most challenging global health issues. BD helps customers enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care.
For more than 30 years, Gilead has been a leading innovator in the field of infectious disease, driving advances in treatment, prevention and cure research. Our breakthroughs across antiviral therapies have helped transform care for people living with various infectious diseases including treatments for HIV, hepatitis C virus and hepatitis B virus. During the COVID-19 pandemic, we deploy our resources and decades of antiviral expertise to provide medicine for COVID-19 treatment for patients and communities to fight against the pandemic.
We recognize that it takes more than medicines to meaningfully improve care for people with life-threatening diseases, so we strive to go beyond the science to address social and structural challenges. At Gilead, we are committed to contributing to a better, healthier world for all, and continue creating possible for the communities that need it most in Asia Pacific and beyond.
The Menarini Group, with its headquarters in Florence, is present in 136 countries around the world with 17,000 employees. With a turnover of 3.6 billion Euro, Menarini today is 13th in Europe out of 5,345 companies and 35th worldwide out of 21,587 (source: IQVIA). Menarini has 6 Research & Development centres and its products are present in the most important therapeutic areas including cardiology, gastroenterology, pneumology, infectious disease, diabetology, anti-inflammatory agents and analgesics. Menarini’s products are manufactured in the Group’s 16 production sites, in Italy and abroad, where more than 583 million packs are produced and distributed over five continents each year. Through its pharmaceutical products, Menarini contributes continuously and with the highest quality standard towards the health of patients all around the world. For further information: www.menarini.com
Menarini is committed to building a strong anti-infectives portfolio; comprised of premium and specialist products. The new Infection in focus identity is a symbol of our commitment. Beyond commitment to product innovation, Menarini is committing to playing a key role in changing the anti-infectives market. In short, Menarini are putting infection in focus.
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda’s global vaccine business is applying innovation to tackle some of the world’s most challenging infectious diseases, such as dengue, Zika and norovirus. The Takeda team brings an outstanding track record and a wealth of knowledge in vaccine development, manufacturing and global access to advance a pipeline of vaccines to address some of the world’s most pressing public health needs.
Every day, millions of patients and caregivers rely on Baxter’s leading portfolio of critical care, nutrition, renal, hospital and surgical products. For more than 85 years, we’ve been operating at the critical intersection where innovations that save and sustain lives meet the healthcare providers that make it happen. With products, technologies and therapies available in more than 100 countries, Baxter’s employees worldwide are now building upon the company’s rich heritage of medical breakthroughs to advance the next generation of transformative healthcare innovations. To learn more, visit www.baxter.com and follow us on Twitter, LinkedIn and Facebook.
Biomedia enables the industrial, R&D and healthcare professionals to make an impact in improving lives by aiding them in their research and testing processes with our product and services.
One of our business entities – SPD Scientific Pte Ltd provides a wide range of biomedical and laboratory equipment, reagents, test-kits, laboratory consumables, as well as diagnostic products, The company plays a key role for customers in industries such as healthcare, academic and government research institutions, pharmaceutical and food and beverages, by providing them with the appropriate tools that aid them in their research and medical discoveries.
Excellence through people. Shaping the future together. Empowering Science, Impacting Lives!
Biosearch Technologies is the comprehensive genomics portfolio from LGC, providing products and services for genomic analysis that support mission critical applications for global customers in human healthcare and molecular diagnostics. We offer tools and technologies to accelerate sample preparation, amplification, cloning, expression, next generation sequencing (NGS), oligonucleotide synthesis, and nucleic acid chemistry.
Globally, we have multiple cGMP manufacturing and ISO 13485-compliant facilities to support supply chain continuity. We collaborate with our customers by complementing their product development pipeline through our robust research grade and cGMP oligonucleotide manufacturing that achieves consistent scale up. We have proven expertise in NGS, isothermal, qPCR-based applications where tools and technologies such as BHQ probes are frequently used in LDTs, ASRs and in vitro diagnostics.
Through our recently acquired Lucigen portfolio, we also offer custom and bulk enzymes and buffers as critical components for molecular diagnostics. OEM services are also available.
GSK is a science-led global healthcare company with a mission to help people do more, feel better and live longer. We research and develop a broad range of innovative products in three primary areas – pharmaceuticals, vaccines and consumer healthcare – that aim to improve people’s health and well-being, ultimately helping them to live life to its fullest and contribute to the prosperity of their communities.
Our goal is to be one of the world’s most innovative, best performing and trusted healthcare companies, bringing differentiated, high-quality and needed healthcare products to as many people as possible.
Our core product categories include diabetes, cancer, vaccines and hospital acute care. We continue to focus our research on conditions that represent some of today’s most significant health challenges – like cancer, hepatitis C, cardio-metabolic disease, antibiotic-resistant infection and Alzheimer’s disease, and we are on the front lines in the fight against emerging global pandemics, such as ebola. We also devote extensive time and energy to increasing access to medicines and vaccines through far-reaching programs that donate and deliver our products to the people who need them. At MSD, we’re applying our global reach, financial strength and scientific excellence to do more of what we’re passionate about: improving health and improving lives. For more information, visit www.msd-singapore.com.
Sysmex Asia Pacific
Sysmex Asia Pacific Pte Ltd is a subsidiary of Sysmex Corporation of Japan. Set up as a Representative Office, it was subsequently established as Sysmex Asia Pacific Pte Ltd in October 2005. Located at the centre of regional market operations, Singapore is Sysmex’s headquarters in the Asia Pacific region.
In Asia Pacific, Sysmex is a market leader in the delivery and implementation of scalable clinical IVD and health IT products and services for clinical laboratories, hospitals and healthcare organisations. Its products and solutions continuously help improve patient clinical services and efficiency advances resulting in cost savings, which in turn translate to the delivery of better patient care.
Globally, Sysmex delivers total solutions in the field of clinical laboratory testing, including haematology, haemostasis, urinalysis, clinical chemistry, immunoassay system, flow cytometry and life science. Through its diverse product portfolio, Sysmex strives to deliver innovative testing tools and surveillance solutions to support antimicrobial stewardship programs in the fight against global infectious disease burdens.